By IGHI guest blogger Chanice Henry, Editor, Pharma IQ & Pharma Logistics IQ
Similar to new Hollywood feature Rampage, a recent study has urged the life sciences industry not to underestimate the dangers that could hide within CRISPR Cas9.
Although the film has been criticised for wildly exaggerating the capabilities of the gene editing technique, it can be recognised for its effort to draw focus from the excitable buzz around CRISPR Cas9 towards the importance of considering the ethics and dangers associated with the tool.
A recent commentary piece also emphasised the importance of methodically debating the potential outcomes of CRISPR within the task of tackling Malaria.
By Dr Michael Templeton, Reader in Public Health Engineering, Department of Civil and Environmental Engineering, Imperial College London
Wednesday, May 25th 2016 marks Africa Day, the 53rd anniversary of the founding of the Organisation of African Unity, the forerunner of the African Union. There have been so many wonderful developments in Africa in the last 53 years, but sadly the quality of life of many of the poorest people in Africa continues to be limited by the burden of a group of debilitating diseases known collectively as neglected tropical diseases (NTDs), which have afflicted millions of Africans since ancient times.
By Professor Kathryn Maitland, Professor of Tropical Paediatric Infectious Diseases and Director of IGHI’s new Centre for African Research and Engagement (ICCARE).
Across large parts of sub-Saharan Africa the major rains have got underway; which typically means that in a few weeks, hospitals will witness a seasonal upsurge of admissions into the children’s wards. Most of these will be children suffering a new bout of malaria, with around ten percent of these malaria admissions having life-threatening complications such a coma (cerebral malaria), severe anaemia (requiring urgent life-saving transfusion) and rapid breathing (to try to compensate for the build up of acids in their bodies).
By Dr Michael Templeton, Faculty of Engineering, Department of Civil and Environmental Engineering, Imperial College London
With World Water Day approaching on 22 March, research at Imperial College London is highlighting yet another example of why access to clean water is so vitally important to human health.
The research is seeking to quantify the role of access to clean water in reducing the odds of becoming infected with the neglected tropical disease schistosomiasis.
A schistosomiasis worm
It has been estimated that 200 million people in developing countries are infected with the parasite causing this disease, which manifests itself in a range of symptoms, including enlargement of the liver and spleen, anaemia, increased risk of bladder cancer, exacerbation of the transmission of HIV and its progression to AIDS, and in extreme cases seizures.
By Professor Alan Fenwick OBE, Director of SCI (Schistosomiasis Control Initiative), Imperial College, London)
A schistosomiasis worm
Schistosomiasis is a type of infection caused by parasites that live in fresh water, such as rivers or lakes, in subtropical and tropical regions worldwide. It is also known as bilharzia.
The Schistosomiasis Control Initiative (SCI) at Imperial College London supports Ministries of Health and Education in 16 countries to deliver medicines to treat people infected with schistosomiasis and three intestinal worms. The medicines are donated by various pharmaceutical companies, Merck KgGA (praziquantel), GSK (albendazle) and Johnson and Johnson (mebendazole), and for the most part, the targets are school aged children.
Gabrielle Prager, Winner of IGHI’s 2013 Student Challenges Competition guides us through her journey throughout the contest and the next steps for her research project.
This is the problem: In 2011, 243 million people required treatment for schistosomiasis. 28.1 million were reported to have received that treatment. Schistosomiasis is a neglected tropical disease. What is it? It is a blood dwelling fluke. How is it treated? Mass Drug Administration with Praziquantel has been the mainstay of most treatment programmes. Uganda was the first country in Africa to initiate a national control programme coordinated by the Ministry of Health with technical and financial support from the Schistosomiasis Control Initiative (SCI).